anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To suppress the voltatilization of a volatile substance, by forming a microcapsule wherein oil of which the solubility to water is 5% or less or an oily solution containing said oil as a solvent is included in the hollow part of an inorg. hollow body. CONSTITUTION:Oil or which the solubility to water is 5% or less or an oily solution containing said oil as a solvent is mixed with an aqueous solution containing a water soluble inorg. compound selected from an alkali metal salt, a salt of a metal belonging to the VIIa group of a Periodic Table or the like to prepare an O/W type emulsion. Subsequently, an org. solvent, of which the solubility to water is 5% or less, is mixed with this O/W type emulsion to prepare an O/W/O type emulsion while an aqueous solution containing a compound, which forms a water insoluble precipitate through the reaction with the aforementioned water soluble inorg. compound, such as alkaline earth metal halide is mixed with the O/W/O type emulsion. Next, the reaction product is filtered and dried to prepare an oil-containing inorg. type microcapsule.
Dexmedetomidine is a selective α2-agonist which induces sedation, anxiolysis and analgesia without respiratory depression. These effects, as well as neuroprotective properties in experimental studies would be ideal in neuroanaesthesia and in neurocritical care. Poor grade SAH patients are treated in intensive care units (ICU). These patients are sedated often with propofol. However, to assess the patient's neurology, the propofol sedation must be stopped and the wakening of the patient may take time. Dexmedetomidine would be more advantageous, allowing wakening during the infusion. However, the effects of dexmedetomidine on cerebral autoregulation are unknown in SAH patients.

15 SAH patients requiring sedation, mechanical ventilation and ICP monitoring will be rolled in to the study.
The invention discloses an ilicis rotundae cortex medicament composition for preventing such diseases as prostatitis and prostatic hyperplasia. The composition is obtained through extraction from barks of llex rotunda thunb. and refinement and is characterized by being formed by pedunculoside, syringin, rotundic acid and other substances. Pharmacological tests prove that the composition has the effect of preventing prostatitis, prostatic hyperplasia and the like. The composition has new application to preparing medicaments for preventing prostatic diseases. Pharmaceutic preparations of the composition are elaborated and can be any one of tablets, capsules, pills, granules, suspensions, dripping pills, ointments and rectal administration preparations such as suppositories.
The invention provides an isopropyl lanolate emulsified balsam. The formula comprises the following raw materials in parts by weight: 3.0 parts of ethoxylated lanolin, 5.0 parts of ozocerite, 2.0 parts of isopropyl lanolate, 0.6 part of borax, 10.0 parts of beewax, defined amount of essence, 44.0 parts of mineral oil, defined amount of preservative, 2.0 parts of glycerin monostearate and 33.4 parts of deionized water. The raw materials have synergistic effects in dosages and physicochemical properties, thus achieving the skin moistening and protecting effects. The PH value of the balsam is close to the PH values of human skins, so that the balsam is non-irritant to skins. Users obviously feel comfortable, soft and moist after using the balsam. The balsam has obvious moistening, softening and lubricating effects.
The present invention relates to a pure traditional Chinese medicinal preparation for treating pulmonary tuberculosis. The main medicines are geckos, aweto, stemona roots, turtle shells and caladium, and the auxiliary medicines are ginseng, donkey-hide gelatin, astragalus roots, spring notoginseng, etc. The present invention is prepared by careful processing, reasonable matching and scientific manufacturing. The medicine has the efficacy of tonifying deficiency, invigorating vital energy, treating pulmonary tuberculosis germs, nourishing yin to reduce pathogenic fire, moistening lungs to arrest cough, replenishing qi to invigorate spleens, promoting blood generation and stop bleeding. The present invention has the advantages of basically no drug resistance, no toxic or side effect, mild medicinal property, stable effect, short course of treatment, high cure rate and difficult recurrence. The present invention also has the efficacy of treating lungs and concurrently benefiting hearts, spleens, stomachs, intestines, livers and kidneys. The present invention has a unique curative effect on pulmonary tuberculosis, scrofula and intestinal tuberculosis.
BACKGROUND: Jaceosidin (JA) is a natural flavone extracted from Artemisia that is used as a food and traditional medicinal herb. It has been reported to possess numerous biological activities. However, the regulatory mechanisms underlying amelioration of hepatic fibrosis remain unclear.
HYPOTHESIS/PURPOSE: We hypothesized that jaceosidin acid (JA) modulates hepatic fibrosis and inflammation.
METHODS: Thioacetamide (TAA) was used to establish an HF mouse model. In vitro, mouse primary hepatocytes and HSC-T6 cells were induced by TGF-β, whereas mouse peritoneal macrophages received a treatment lipopolysaccharide (LPS)/ATP.
RESULTS: JA decreased serum transaminase levels and improved hepatic histological pathology in TAA-treated mice stimulated by TAA. Moreover, the expression of pro-fibrogenic biomarkers associated with the activation of liver stellate cells was downregulated by JA. Likewise, JA down-regulated the expression of vestigial-like family member 3 (VGLL3), high mobility group protein B1 (HMGB1), toll-like receptors 4 (TLR4), and nucleotide-binding domain-(NOD-) like receptor protein 3 (NLRP3), thereby inhibiting the inflammatory response and inhibiting the release of mature-IL-1β in TAA-stimulated mice. Additionally, JA suppressed HMGB1 release and NLRP3/ASC inflammasome activation in LPS/ATP-stimulated murine peritoneal macrophages. JA decreases the expression of pro-fibrogenic biomarkers related to liver stellate cell activation and inhibits inflammasome activation in mouse primary hepatocytes. It also down-regulated α-SMA and VGLL3 expressions and also suppressed inflammasome activation in HSC-T6 cells. VGLL3 and α-SMA expression levels were decreased in TGF-β-stimulated HSC-T6 cells following Vgll3 knockdown. In addition, the expression levels of NLRP3 and cleaved-caspase-1 were decreased in Vgll3-silenced HSC-T6 cells. JA enhanced the inhibitory effects on Vgll3-silenced HSC-T6 cells. Finally, Vgll3 overexpression in HSC-T6 cells affected the expression levels of α-SMA, NLRP3, and cleaved-caspase-1.
CONCLUSION: JA effectively modulates hepatic fibrosis by suppressing fibrogenesis and inflammation via the VGLL3/HMGB1/TLR4 axis. Therefore, JA may be a candidate therapeutic agent for the management of hepatic fibrosis. Understanding the mechanism of action of JA is a novel approach to hepatic fibrosis therapy.
BACKGROUND: The Oxidative Balance Score (OBS), which quantifies the balance between antioxidants and pro-oxidants influenced by diet and lifestyle, is crucial given oxidative stress's significant role in Chronic Kidney Disease (CKD). This study aims to determine the association between OBS and CKD using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018.
METHODS: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018. OBS was constructed from a detailed array of 20 factors, including dietary nutrients and lifestyle behaviors. The relationship between OBS and CKD risk was evaluated using weighted logistic regression models, adjusted for potential confounders, with a generalized additive model (GAM) examining non-linear associations. Subgroup analyses and interaction effects across diverse demographic and clinical groups, along with sensitivity analyses, were performed to validate the findings.
RESULTS: Among 32,120 participants analyzed, 4,786 were identified with CKD. Fully adjusted weighted logistic regression analysis revealed that each unit increase in OBS was associated with a 2% reduction in CKD prevalence [OR: 0.98 (0.98-0.99), P < 0.001]. Higher OBS quartiles were significantly correlated with a decreased CKD risk [Q4 vs. Q1: OR: 0.82 (0.68-0.98), P = 0.03; P for trend = 0.01]. The GAM and smoothed curve fit indicated a linear relationship between OBS and the risk of CKD. Stratified and sensitivity analyses further substantiated the inverse relationship between OBS and CKD prevalence.
CONCLUSIONS: Our findings from the NHANES data affirm a significant inverse association between OBS and CKD risk in the U.S. population, underscoring the role of optimizing dietary and lifestyle factors in managing CKD risk. These results advocate for incorporating OBS considerations into CKD prevention and treatment strategies.
After delivering the "AWARD" advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183).
PURPOSE:The titled pharmaceutical preparation capable of using economically and effectively cycloheximide useful as a repellent for rats and a fungicide for plants, obtained by using a cycloheximidecontaining solution as a core substance and covering the core substance with a wall substance. CONSTITUTION:Cycloheximide (CHI for short) shown by the formula is dissolved in a solvent (e.g., alcohol, ketone, ether, etc.) dissolving it stably to give a solution, which is used as a core substance, and the core substance is coated with a capsule wall substance (e.g., urea resin, melamine resin, phenolic resin, etc.). Microcapsules are prepared by using in situ method, etc. These capsules prevent reduction in titer of crystalline CHI, and shows approximately four times as much chemical effect as that of existing CHI crystal. They are a CHI preparation having improved heat resistance and chemical resistance. They are also useful for blending with processed articles (e.g., cable, furniture, packaging container, etc.) of synthetic resins comprising mainly PVC.
PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
The present invention relates to a quick-acting Chinese medicine pharmaceutical formulation for treating liver cirrhosis, which comprises bupleurum root, cape jasmine fruit, virgate wormwood herb, pinellia tuber, largehead atractylodes rhizome, costustoot, red sage root, zedoray, scirpus, gentian root, Indian bread, areca peel and oriental waterplantain rhizome. The medicine combines an ancient secret prescription with a modern medical theory, and is refined with pure Chinese medicines. The present invention has functions of calming the liver, removing blood stasis, promoting qi circulation to induce diuresis, eliminating warm, removing gall and clearing away heat and toxic material, which is a specific medicine for treating liver cirrhosis and hepatitis B. The present invention has special curative effects on damp-heat liver cirrhosis and icteric liver cirrhosis. The cure rate of the Chinese medicine pharmaceutical formulation reaches 91%, and the effective rate reaches 98%, which is a new academic theory breakthrough in Chinese medicine field. The Chinese medicine has the advantages of removing gall, promoting qi circulation to induce diuresis, activating blood circulation to dissipate blood stasis, etc., which makes up for the deficiencies of the treatment of the diseases by western medicines, and obtains good curative effects quickly.
Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
This study aims to assess the therapeutic role of repetitive transcranial magnetic (rTMS) on parkinson's patients with dysphagia. Thirty PD patients with dysphagia using UK bank criteria for PD will recruited from outpatient clinic in Assuit University. All patients were admitted at, Neuropsychiatric Department, Assiut University Hospital/ Assiut, Egypt. Each patient fulfilled the inclusion criteria as spontaneous swallows should be identified clearly when patients cannot perform voluntary swallows using clinical examination test. The patients will be allocated randomly into two groups using closed envelops one of which will receive real sessions of high frequency rTMS (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days with repeated booster session every month during the period of follow up among three months. the other will receive sham sessions. All subjects after receiving the rTMS will be followed up by selected clinical rating scales at different intervals Pre session, post 10 sessions, after one, two and three months.
<P>PROBLEM TO BE SOLVED: To provide a medical document preparation supporting device for improving the preparing efficiency of a medical document.  <P>SOLUTION: A control terminal 200 adds header information indicating the imaging position or classification of an imaging device 100 to an original image photographed by the imaging device. Original image information added with the header information is processed by an image processor 300 to generate a diagnostic image, and the header information indicating an image processing mode or the like is added. At the time of preparing a diagnostic reading report by the image processor 300, a diagnostic image to be fetched is designated. The image processor 300 specifies the imaging device and the imaging site by referring to the header information of the designated processing image, and designates a corresponding dictionary file. When a person in charge voice-inputs his opinion to the diagnostic reading report, voice recognition is executed by using the designated dictionary file.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:A drug, containing human gamma-globulin as a principal component and useful for treating spontaneous autoimmune hemolytic anemia without side effects. CONSTITUTION:A remedy for spontaneous autoimmune hemolytic anemia containing human gamma-globulin as a principal component. The spontaneous autoimmune hemolytic anemia (hereinafter abbreviated to IAIHA) shows the symptoms by the erhtyrocytic autoantibody, and the similar immunological abnormality is considered to be present at the back thereof. When the human gamma-globulin is administered to a patient with IAIHA, the numbers of the hemoglobin and erythrocytes are increased and remarkable improvement in symptoms is recognized without any observed side effect. The above-mentioned pharmaceutical is dissolved in, e.g. distilled water for injection, preferably in about 10-100mg/ml concentration and administered by drip or intravenous injection, etc. However, the administration is carried out one a day for several days depending on the variation in number of the hemoglobin and erythrocytes until the numbers are constant. Preferably, the remedy is administered to patients with spontaneous IAIHA, chronic and intractable patients with IAIHA or those for which steroid is difficult to use.
The term central sensitization (CS) was first used by Wolf in 1988 and was explained as the increase in pain sensitivity with the amplification of neuron-derived signals in the central nervous system. With the development of CS, a decrease in the pain threshold and an increase in generalized sensitivity occur. There is no method for the diagnosis of CS is accepted as a gold standard. Clinical scales and quantitative sensory testing (QST) is used for this purpose widely. In addition, the well-known scale used for the evaluation of CS is the Central Sensitization Inventory (CSI), developed for detect CS in chronic pain patients. The use of CSI, which is more practical to use, is becoming widespread because QST takes time, is costly and requires experienced practitioners. Considering the place of sensory hypersensitivity in the diagnosis of CS and the application difficulties of QST, the Sensory Hypersensitivity Scale was developed in 2016. This scale includes 25 questions in the form of a Likert scale and questions the increase in modality-specific (touch, taste, hearing, etc.) sensitivity as well as the general sensitivity increase. Especially in chronic pain conditions, there is an increase in the evidence regarding the development of CS day by day, and the need for auxiliary tools in diagnosis is increasing in parallel. In this study, it was planned to show the Turkish reliability and validity the Sensory Hypersensitivity Scale.
Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Unlike previous frailty index, mFI-5 uses a small number of variables readily available in a patient's history, including functional status (partial or complete dependence), history of diabetes, COPD, congestive heart failure, and hypertension requiring medication. 1 point is assigned to each variable. Functional status refers to needing some or all of the assistance of others in daily activities, including bathing, eating, dressing, going to the toilet, moving, traveling, and more. The mFI-5 score was calculated by increasing the number of variables per patient Patients were divided into 3 groups based on their mFI-5: frail group (mFI-5, 2-5) , prefrail group (mFI-5, 1) and robust group (mFI-5, 0). The range of the mFI-5 is from 0 to 5 with increments of 1, and increasing the mFI-5 implies increasing frailty.
The objective of this study was to evaluate the susceptibilities of pathogens isolated from cultures within the first 7 days of admission to the burn center and in the absence of healthcare-associated infection risk factors (HAIRF) to determine if current empiric antibiotics can be narrowed for refinement of an empiric antibiotic prescribing pathway according to the suspected source. A 3-year sample of patients and cultures was utilized in hopes of obtaining at least 30 isolates of the most common pathogens and their respective susceptibilities. A total of 268 clinically relevant (e.g., deemed infectious, versus colonization) pathogens were included in the final sample with sources including wounds, respiratory, blood, urine, and bone. Of the 268 pathogens included, 45% were Gram-negative and 69% of all pathogens were isolated from wound cultures. The existing empiric pathway, vancomycin plus cefepime, covered 98% and 84% of all Gram-positive and Gram-negative pathogens, respectively. In patients without HAIRF, coverage rose to 98% and 90%, respectively. Initial use of vancomycin and cefepime remains adequate for pathogens isolated within 1 week of admission in patients without HAIRF. For pneumonias, a narrower spectrum beta-lactam would not sufficiently cover respiratory pathogens isolated within the first week of admission. Regarding early wound infections, difficult-to-treat pathogens remain as a rare isolate of wound cultures within 1 week of admission.
This will be a pilot trial exploring the ability of a novel combination ("H2M") of molecular hydrogen (an antioxidant) and minocycline (a widely used antibiotic known to inhibit the activation of matrix metallo-proteinase-9 and poly(ADP-ribose) polymerase), to protect brain tissue from ischemia/reperfusion injury that occurs during and after an ischemic stroke. Both hydrogen and minocycline have excellent safety profiles, have been previously demonstrated individually to reduce infarction in animal models of stroke, and have potentially synergistic mechanisms of action against ischemic brain damage. The mechanisms of action of both agents would be specifically relevant to patients receiving tissue plasminogen activator (tPA) or thrombectomy, and achieving some degree of therapeutic reperfusion.

This will be a double blinded, placebo-controlled trial. Eligible and willing subjects will be randomly assigned to be treated with either H2M or placebo, in addition to standard treatments. The treatment with H2M or placebo will start as soon as possible after diagnosis of stroke, and continue for three days (hydrogen) and five days (minocycline) respectively. Measures of stroke severity and disability will be recorded at baseline, and through a follow-up phone call (45 days) and clinic visit (90 days).